Alpha Teknova - TKNO STOCK NEWS

Teknova reported total revenue of $36.9 million for 2021, marking an 18% increase from 2020. Excluding Sample Transport revenue, the total was $35.4 million, up 31%. The fourth quarter revenue was $10.1 million, consistent with 2020, and 26% higher at $9.6 million when excluding Sample Transport. However, the net loss for 2021 was $9.8 million, or $0.61 per diluted share, a decline from 2020's net income. Looking ahead, Teknova projects revenue between $44 million and $48 million for 2022, driven by growth in Lab Essentials and Clinical Solutions.

Alpha Teknova (Nasdaq: TKNO) has announced it will report its financial results for the fourth quarter and full year 2021 on March 15, 2022, after market close. A webcast and conference call will follow at 4:30 p.m. ET. This session will provide insights into the company's performance, focusing on critical reagents for drug therapies and diagnostics. The company is known for its agility in delivering custom products for bioprocessing and molecular diagnostics.

Alpha Teknova (Nasdaq: TKNO) announced preliminary unaudited revenue for Q4 2021 of $10.0 to $10.1 million, including approximately $0.5 million from Sample Transport. Excluding this, revenue ranges from $9.5 to $9.6 million, marking a 25% increase year-over-year. Despite this growth, total revenue reflects a 1% decline compared to Q4 2020. The company will present its detailed financials around March 15, 2022, and will participate in investor conferences on March 9 and March 23, 2022.

Alpha Teknova, a key provider of critical reagents for biopharmaceuticals, will participate in the BTIG MedTech, Digital Health, Life Science, and Diagnostic Tools Conference from February 15-17, 2022. The company's President, Stephen Gunstream, and CFO, Matt Lowell, will host a virtual fireside chat on February 17 at 1:00 p.m. ET. They will discuss company highlights, market trends, and growth drivers. Teknova specializes in custom products for bioprocessing, offering high-quality reagents for applications like cell and gene therapy.

Alpha Teknova, Inc. (Nasdaq: TKNO) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. This index tracks the performance of Nasdaq-listed biotech stocks, highlighting Teknova's eligibility based on market capitalization, trading volume, and listing duration. CEO Stephen Gunstream praised the company's milestones since its IPO in June 2021, asserting that this recognition validates Teknova's efforts in advancing new therapies and diagnostics. The move is expected to enhance visibility among investors and position Teknova favorably within the biotech sector.

Teknova (Nasdaq: TKNO), based in Hollister, California, is a key player in providing reagents for biopharmaceutical development. The company will participate in two investor conferences: the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021, with a pre-recorded presentation on November 22 at 10:00 a.m. ET, and the Stephens 23rd Annual Investment Conference in Nashville, TN, from December 1 to 3, 2021, featuring a fireside chat on December 3 at 8:00 a.m. CT. Webcasts accessible on their Investor Relations page will remain available for 90 days.

Teknova reported total revenue of $9.4 million for Q3 2021, marking a 5% year-over-year increase. When excluding Sample Transport revenue, the company saw a notable 26% growth. Despite a strong cash position of $98.0 million, gross profit declined to $4.3 million with a gross margin of 45.4%, down from 56.6% in Q3 2020. Operating expenses surged to $8.2 million due to strategic hires and infrastructure investments, resulting in a net loss of $3.3 million for the quarter. Adjusted EBITDA was negative $2.7 million, contrasting significantly with a positive $2.7 million in the same period of 2020.

Teknova (Nasdaq: TKNO) has appointed Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President of Marketing. Gelhaus, with over 15 years of experience in life sciences, aims to build a successful sales team to drive growth. Henry, a veteran in branding, will bring a consumer-oriented approach to the company’s marketing strategy. This leadership change is expected to enhance Teknova’s capabilities in commercial operations and brand strategy, potentially accelerating growth in the life sciences sector.

Alpha Teknova, Inc. (TKNO) plans to disclose its third-quarter 2021 financial results on November 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, allowing investors to access the discussion live via their website. Teknova specializes in providing essential reagents for biopharmaceutical development, focusing on agility and customization. The company’s proprietary processes cater to various applications like gene therapy and molecular diagnostics, aiming to accelerate breakthroughs in life sciences.